-
2025-523555-66-00
5
Myelofibrosis
-
2025-523586-18-00
5
Non-Small Cell Lung Cancer
-
2025-524181-26-00
4
relapsed/refractory multiple myeloma
-
2025-524316-11-00
5
Primary Progressive Multiple Sclerosis (PPMS)
-
2025-524408-30-01
5
Metastatic hormone-sensitive prostate cancer
-
2025-524613-89-00
9
HER2 positive advanced breast cancer
-
2025-524646-94-00
11
Obstetrics – Preeclampsia
-
2025-524810-28-00
5
Acute Promyelocytic Leukemia
-
2025-523269-31-00
3
2026-06-02
Hormone receptor-positive early breast cancer in post-menopausal women
-
2025-524265-24-00
5
2026-05-21
Dyslipidemia at High to Very High Cardiovascular Risk
-
2025-524498-17-00
10
2026-05-08
Pretreated Unresectable Locally Advanced or Metastatic human epidermal
-
2025-524366-21-00
5
2026-04-29
treatment-naive Chronic Lymphocytic Leukemia
-
2024-512436-29-00
11
2026-03-27
CARDIOVASCULAR DISEASES
-
2025-521884-12-00
5
2026-03-19
First line triple-negative breast cancer (TNBC)
-
2024-519444-33-00
5
2026-03-12
HER2-expressing endometrial cancer (IHC 3+/2+)
-
2025-522553-19-00
10
2026-02-25
Symptomatic genetic and familial dilated cardiomyopathy.
-
2024-520027-88-00
4
2026-02-12
Patients with hormone receptor-positive (HR+) breast cancer
-
2024-520433-76-00
4
2026-01-08
Newly Diagnosed Multiple Myeloma
-
2023-505661-89-00
4
2025-12-19
Early-stage, Hormone Receptor (HR)-positive / Human Epidermal Growth F
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2025-522455-26-00
9
2025-12-17
Acute Ischemic Stroke
-
2025-522070-36-00
5
2025-12-15
immune thrombocytopenia (ITP)
-
2025-520982-39-00
5
2025-12-09
Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
-
2025-521251-24-00
4
2025-12-01
Non-Small cell lung cancer (NSCLC)